Skip to main content

Table 1 AL Staging according to the revised Mayo AL staging tool [55]

From: Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers

Number of abnormal laboratory tests Stage (according to revised staging system) Median Overall Survival (months) 5-year Survival
0 I 94.1 59%
1 II 40.3 42%
2 III 14 20%
3 IV 5.8 14%
  1. (Laboratory tests: cTnT ≥0.025 ng/mL, NT-ProBNP ≥1800 pg/mL, dFLC≥18 mg/dL)